If you have been reading about GHRH receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-15. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
In 1938 Somogyi published findings showing that excessive insulin can make diabetes management unstable and increase the difficulty of treatment. The Chronic Somogyi rebound, a form of post-hypoglycemic hyperglycemia that Somogyi theorized could occur as a defensive mechanism, is named for him. It can be confused with the Dawn phenomenon and whether or not Somogyi's theory is actually correct is still contested. In 1949, Somogyi argued against the use of high doses of insulin on the grounds that it was a potentially dangerous form of treatment. He also argued that many diabetic patients could successfully manage their conditions through a combination of diet and weight loss. In 1969, Somogyi had a stroke. He died on 21 July 1971.
=== Phenylbutyrate therapy === Sodium phenylacetate/benzoate or sodium phenylbutyrate has been shown to reduce BCAA in a clinical trial done February 2011. Phenylbutyrate treatment reduced the blood concentration of BCAA and their corresponding BCKA in certain groups of MSUD patients and may be a possible adjunctive treatment.
Alonso de Ojeda (who had sailed with Columbus) reached the Guajira Peninsula in 1499. Spanish explorers, led by Rodrigo de Bastidas, made the first exploration of the Caribbean coast in 1500. Christopher Columbus navigated near the Caribbean in 1502. In 1508, Vasco Núñez de Balboa accompanied an expedition to the territory through the region of Gulf of Urabá and they founded the town of Santa María la Antigua del Darién in 1510, the first stable settlement on the continent. Santa Marta was founded in 1525, and Cartagena in 1533. Spanish conquistador Gonzalo Jiménez de Quesada led an expedition to the interior in April 1536, and christened the districts through which he passed "New Kingdom of Granada". In August 1538, he provisionally founded its capital near the Muisca cacicazgo of Muyquytá, and named it "Santa Fe". The name soon acquired a suffix and was called Santa Fe de Bogotá. Two other notable journeys by early conquistadors to the interior took place in the same period. Sebastián de Belalcázar, conqueror of Quito, traveled north and founded Cali, in 1536, and Popayán, in 1537; from 1536 to 1539, German conquistador Nikolaus Federmann crossed the Llanos Orientales and went over the Cordillera Oriental in a search for El Dorado, the "city of gold". The legend and the gold would play a pivotal role in luring the Spanish and other Europeans to New Granada during the 16th and 17th centuries. The conquistadors made frequent alliances with the enemies of different indigenous communities.
Sources: en.wikipedia.org
==== 2700–2799 ==== Social Security (Introduction of Disability Living Allowance) (Amendment) (No. 3) Regulations 1993 (S.I. 1993/2704) Capital Allowances (Corresponding Northern Ireland Grants) Order 1993 (S.I. 1993/2705) Building Societies (Designation of Qualifying Bodies) (No. 3) Order 1993 (S.I. 1993/2706) Education (No. 2) Act 1986 (Amendment) Order 1993 (S.I. 1993/2709) Housing Renovation etc. Grants (Grant Limit) (Amendment) Order 1993 (S.I. 1993/2711) Reconstitution of the River Ouzel Internal Drainage Board Order 1993 (S.I. 1993/2712) Placing on the Market and Supervision of Transfers of Explosives Regulations 1993 (S.I. 1993/2714) Food Labelling (Scotland) Amendment Regulations 1993 (S.I. 1993/2731) Teachers (Education, Training and Recommendation for Registration) (Scotland) Regulations 1993 (S.I. 1993/2732) Portsmouth Mile End Quay (Berth No. 2 Extension) Harbour Revision Order 1993 (S.I. 1993/2733) Criminal Justice Act 1993 (Commencement No. 3) Order 1993 (S.I. 1993/2734) Social Security (Contributions) (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/2736) Public Service Vehicles (Registration of Local Services) (Amendment) Regulations 1993 (S.I. 1993/2752) Public Service Vehicles (Operators' Licences) (Amendment) Regulations 1993 (S.I. 1993/2753) Public Service Vehicles (Traffic Commissioners: Publication and Inquiries) (Amendment) Regulations 1993 (S.I. 1993/2754) Copyright (Certification of Licensing Scheme for Educational Recording of Broadcasts) (Open University Educational Enterprises Limited) Order 1993 (S.I.
Ca(OH)2 + x/8 S8 → CaSx + by-products (S2O2−3, SO2−3, SO2−4) as reported in a document of the US Department of Agriculture (USDA). This reaction is poorly understood because it is vague and involves the reduction of elemental sulfur, and no reductant appears in the equation, while sulfur oxidation products are also mentioned. The initial pH of the solution imposed by poorly soluble hydrated lime is alkaline (pH = 12.5) while the final pH is in the range 11–12, typical for sulfides, which are also strong bases. When the hydrolysis of calcium sulfide is taken into account, the individual reactions for each of the by-products are:
==== Movies ==== Fantasia (1940), with lead visualist Oskar Fischinger, may have been inspired by mescaline-induced visuals. Fear and Loathing in Las Vegas (1998) starring Johnny Depp and Benicio del Toro featured mescaline use. The Matrix (1999) by the Wachowskis included a brief mention of mescaline. The Royal Tenenbaums (2001) features a character named Eli Cash (Owen Wilson) who regularly takes mescaline. Crystal Fairy & the Magical Cactus (2013) starring Michael Cera and Gaby Hoffmann was about taking mescaline in the form of the San Pedro cactus.
CRFB1 (IFNAR2-1) + CRFB5 (IFNAR1) binds group I CRFB2 (IFNAR2-2) + CRFB5 (IFNAR1) binds group II CRFB6 (IFNGR2) + 2× CRFB13 (IFNGR1-2) binds IFNg CRFB6 (IFNGR2) + 2× CRFB17 (IFNGR1-1) binds IFNgrel CRFB6 (IFNGR2) + CRFB13 (IFNGR1-2) + CRFB17 (IFNGR1-1) binds IFNg and possibly IFNgrel CRFB12 (IFNUR1) + CRFB4 (IL-10R2) binds type IV The split of type I into fish groups I, II and the many amniote Greek-letter groups happened independently, after the two groups of animals had diverged from each other. As a result, the only level of orthology between these grouping is that fish type I is as a whole orthologous to amniote type I. Much like in amniotes, the new copies of interferon have subfunctionalized in teleost fish.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.